Redox Signaling and Neural Control of Cardiovascular FunctionView this Special Issue
Research Article | Open Access
Jeffrey Hatcher, He Gu, Zixi (Jack) Cheng, "SOD1 Overexpression Preserves Baroreflex Control of Heart Rate with an Increase of Aortic Depressor Nerve Function", Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3686829, 11 pages, 2016. https://doi.org/10.1155/2016/3686829
SOD1 Overexpression Preserves Baroreflex Control of Heart Rate with an Increase of Aortic Depressor Nerve Function
Overproduction of reactive oxygen species (ROS), such as the superoxide radical (), is associated with diseases which compromise cardiac autonomic function. Overexpression of SOD1 may offer protection against ROS damage to the cardiac autonomic nervous system, but reductions of may interfere with normal cellular functions. We have selected the C57B6SJL-Tg (SOD1)2 Gur/J mouse as a model to determine whether SOD1 overexpression alters cardiac autonomic function, as measured by baroreflex sensitivity (BRS) and aortic depressor nerve (ADN) recordings, as well as evaluation of baseline heart rate (HR) and mean arterial pressure (MAP). Under isoflurane anesthesia, C57 wild-type and SOD1 mice were catheterized with an arterial pressure transducer and measurements of HR and MAP were taken. After establishing a baseline, hypotension and hypertension were induced by injection of sodium nitroprusside (SNP) and phenylephrine (PE), respectively, and ΔHR versus ΔMAP were recorded as a measure of baroreflex sensitivity (BRS). SNP and PE treatment were administered sequentially after a recovery period to measure arterial baroreceptor activation by recording aortic depressor nerve activity. Our findings show that overexpression of SOD1 in C57B6SJL-Tg (SOD1)2 Gur/J mouse preserved the normal HR, MAP, and BRS but enhanced aortic depressor nerve function.
Autonomic control of the cardiovascular system is compromised in multiple disease conditions such as diabetes [1–3], hypertension , sleep apnea , and aging [6–9]. One of the autonomic functions impacted is the baroreflex control of heart rate (HR). Baroreflex sensitivity (BRS) is a measure of the strength of baroreflex control of heart rate in response to changes in arterial pressure, and it is an important index of cardiac autonomic function. Several clinical conditions are strongly associated with an attenuated BRS, including hypertension , vasovagal syncope , and heart failure , and it is considered as an independent risk factor for cardiac failure and sudden death [13–15].
The baroreflex arc is composed of multiple neural components including the aortic and carotid baroreceptors, the nucleus tractus solitarius (NTS), paraventricular nucleus of the hypothalamus (PVN), nucleus ambiguus (NA), caudal ventrolateral medulla (CVLM), and rostral ventrolateral medulla (RVLM) [16–19]. An increase in levels of reactive oxygen species (ROS) in these neural components of the baroreflex arc including the carotid and aortic baroreceptors [20–23], NTS [24–26], PVN , and RVLM [28–30] are seen in conditions such as diabetes, sleep apnea, hypertension, and heart failure.
Several lines of research suggest that antioxidant therapy, whether applied locally [20, 21, 31] or systemically [32–34], can restore normal baroreflex function in some of these disease states, ostensibly by decreasing levels of ROS species. However, ROS, including the superoxide radical, play critical roles in regulating the firing properties of neurons . For instance, the ANGII signaling pathway is dependent upon superoxide anions generated by the actions of NADPH oxidase [24, 36]. Indeed, some studies have noted that superoxide scavenging can affect central regulation of heart rate and blood pressure in healthy animals as well as some disease models [31, 32, 37].
Conversely, other investigations have suggested SOD1 overexpression can be detrimental to neuronal tissues. Some studies [38, 39] found evidence of mild axonal degeneration and some death of motor neurons in mice overexpressing hSOD1. In addition, increased lipid peroxidation [40, 41], increased sensitivity to kainic acid excitotoxicity , and impaired recovery following nerve injury  have been reported in hSOD1 transgenic mice. Though SOD1 overexpression is protective up to a certain level, further increases in expression may contribute to peroxide formation and deleterious sequela for the tissues [44, 45]. SOD1 overexpression has also been investigated as a contributor to the pathology of Down syndrome, a condition in which SOD1 overexpression is well documented [46–48].
All together, the available evidence from the literature has suggested that SOD1 overexpression can have either protective or detrimental effects on tissues. Therefore, we need to consider if hSOD1 overexpression in animals can affect the neural components of the baroreflex loop in healthy animals. Only then, we can consider any potential benefits of SOD1 overexpression in chronic intermittent hypoxia-, diabetes-, and aging-induced impairment of baroreflex arc as shown in our previous studies [49–57]. In the present study, we have determined the effects of hSOD1 overexpression in transgenic mice on several physiological variables [arterial pressure (AP), heart rate (HR), baroreflex sensitivity (BRS), and aortic depressor nerve function] compared to controls. Our data indicated that hSOD1 overexpression in transgenic mice did not alter the values of AP, HR, and baroreflex sensitivity but enhanced aortic depressor nerve function. This study will provide baseline data on the hSOD1 overexpressing mouse line in order to facilitate future studies on possible baroreflex protective effects of overexpressed SOD1 in murine disease models.
2. Materials and Methods
Mice (C57BL/6j 3-4 mo, ) were used as controls for the transgenic human Cu/Zn SOD overexpressing mice (C57B6SJL-Tg (SOD1)2 Gur/J, Jackson catalog # 002297, ). Procedures were approved by the University of Central Florida Animal Care and Use Committee and followed the guidelines established by the National Institutes of Health. Efforts were made to conduct the experiments humanely and to minimize the numbers of animals used.
2.1.1. Surgical Procedure
The surgical procedure has been described previously in detail . Briefly, mice were anesthetized with 3% isoflurane inhalation and maintained with 1% in a 95% O2 and 5% CO2 through a tracheal tube which was connected to a rodent ventilator, as in our previous studies [51–53].
Depth of anesthesia was carefully monitored by eye blink, withdrawal reflexes (toe and tail pinch), and fluctuations of AP. Body temperature was maintained at 37 ± 1°C with a homeostatic plate and a rectal probe (ATC 1000; World Precision Instrument, Sarasota, FL, USA). The tips of plastic catheters (polyethylene-50) were tapered to ~0.3 mm diameter, the right femoral artery and left femoral vein were exposed, and the tapered ends of the two catheters were filled with heparinized saline and inserted into the femoral artery and vein. Measurement of AP was through the artery. Vasoactive drugs sodium nitroprusside (SNP) and phenylephrine (PE) were infused into the femoral vein using a microinfusion pump. These mice were used for AP, HR, baroreflex bradycardia and tachycardia, and aortic depressor nerve (ADN) recordings.
2.1.2. Baroreflex Sensitivity
The blood pressure catheter was connected to a pressure transducer (MIT0699, AD instruments) which was connected to the PowerLab Data Acquisition System (PowerLab/8 SP). Baseline values of mean arterial pressure (MAP) and HR and the MAP and chronotropic responses to sequential SNP/PE applications were measured using Chart 5 software (AD instruments). SNP and PE (Sigma, St. Louis, MO, USA) were freshly prepared, diluted in 0.9% NaCl, and infused by sequential bolus injections. SNP [2.3 ± 0.1 μg (C57) versus 2.2 ± 0.1 μg (SOD1) in 0.1 μg/μL saline, ] was first injected, and after 10–20 s PE [8.1 ± 0.1 μg (C57) versus 6.9 ± 0.4 μg (SOD1) in 1 μg/μL saline, ] was then injected. Such doses of sequential bolus injections of SNP/PE could induce a fast and large decrease followed by an increase of the AP. The measurement of decrease and increase in the AP was completed in ~1 min to reduce possible baroreflex resetting. Using these doses, MAP decreases and increases were quite comparable in control and SOD1 mice. Baseline values of MAP and HR were measured from a 30 s interval before SNP injection. After injections, MAP and HR returned to baseline values normally within 10–20 min. HR responses to MAP changes induced by sequential administration of SNP and PE included two phases: tachycardiac and bradycardic responses. During the tachycardiac (SNP) phase, MAP and HR changes were measured in the time window as indicated by a light gray box in Figure 1, that is, the baseline of MAP to the nadir of MAP. During the bradycardic (PE) phase, MAP and HR changes were measured in the time window as indicated by a dark gray box in Figure 1, that is, from the peak of the HR to the nadir of the HR. The MAP and corresponding HR were sampled and averaged every second. We applied linear regression analysis of the ΔHR-ΔMAP relationship for each animal, and the slope of the regression line was used as an indicator for baroreflex sensitivity (BRS) as previously described . Data obtained for SNP and PE injections were averaged separately and reconstructed as separated regression lines for each group.
2.2. Baroreceptor Afferent Function
The aortic depressor nerve (ADN) on the left side was identified in the cervical region using a dissecting microscope. The left ADN was carefully isolated from surrounding connective tissues with fine glass tools to avoid stretching or injury of nerve. After that, the left ADN was placed on miniaturized bipolar platinum electrodes (outer diameter: 0.12-mm). The nerve and electrodes were soaked in mineral oil. Aortic depressor nerve activity (ADNA) was amplified (×10,000) with the band-pass filters set between 300 and 1000 Hz by an AC Amplifier (Model 1800, A-M Systems, Sequim, WA, USA). The ADNA, integrated ADNA, phasic arterial pressure (PAP), HR, ECG, and body temperature were all recorded and simultaneously displayed on different channels of the PowerLab System. Chart 5.2 software and Sigma Plot 9.0 were used for data acquisition, analysis, and presentation. All ADNA for analysis had a signal-to-noise ratio > 10 : 1.
The ADNA signal occurred as rhythmic bursts that exhibited cardiac cycles and were synchronized with PAP (Figure 3). ADNA signal was integrated using a 10 ms time constant to obtain the integrated ADNA (Int. ADNA). The “ADNA silent” or the “noise level” between the ADNA bursts was averaged from 30 “ADNA silent” intervals and was used to determine the noise level for Int. ADNA as shown in Figure 3. This averaged noise level was subtracted from original Int. ADNA signal to obtain the corrected Int. ADNA with the averaged noise level of 0 μV· s. The corrected Int. ADNA and MAP were used to construct baroreceptor afferent function curves using logistic sigmodal function. For simplicity, we used Int. ADNA for corrected Int. ADNA in the text below. The baroreceptor function curve was calculated at the rising phase of PE-induced AP increase starting from the nadir of the SNP-induced fall in AP to the maximum of the AP increase. R waves of ECG signal were used to automatically define cardiac cycles by the Chart 5.2 Macro function (arrows in Figure 3). The baroreceptor function curve was fitted by plotting the percent (%) of change of the mean Int. ADNA per cardiac cycle relative to the Int. ADNA baseline value before drug administration against MAP using a sigmoid logistic function . The logistic function for Int. ADNA used the mathematical expression: , where , . ADNA (% baseline), = maximum − minimum (range), Int. ADNA (range), = slope coefficient, = MAP at 50% of the Int. ADNA range (), and = maximum Int. ADNA.
The and were calculated from the 3rd derivative of the logistic function, and they were expressed as and . The maximum slope or gain () was calculated at from the 1st derivative of the logistic function: . Approximately 200–500 data points measured over 30–50 s were used to construct a baroreceptor function curve using Sigma Plot software. The squared correlation coefficient was used to determine the goodness of curve fitting.
2.3. Statistical Analysis
Data were presented as means ± S.E. Student’s -test was used to compare the difference of HR, MAP, slopes of the regression lines, and parameters of the baroreceptor function curves between groups. Differences were considered significant at .
3.1. MAP, HR, and SNP/PE-Induced MAP Changes
hSOD1 overexpression did not alter baseline MAP and HR, and SNP-induced minimums and PE-induced maximums for MAP changes in C57 and SOD1 mice were comparable (Table 1), which allowed us to investigate baroreflex control of HR over a similar range of blood pressure changes (see the following).
3.2. Baroreflex Sensitivity
The original recordings of HR changes (ΔHR) in response to sequential injections of SNP and PE were shown in Figure 1. SNP infusion (light gray box) decreased AP which induced a HR increase (tachycardiac phase). PE infusion (dark gray box) resulted in an increase in AP that drove a baroreflex-mediated reduction in heart rate (bradycardic phase). Tachycardiac and bradycardic responses (ΔHR) against ΔMAP were fitted using separate regression lines for both C57 and SOD1 animals (/group), respectively. The slopes of the regression lines represent the baroreflex sensitivity (BRS) and they were similar (Figures 2(a) and 2(b)) for the tachycardiac phase [C57: −0.57 ± 0.06 bpm/mmHg, SOD1: −0.61 ± 0.08; ] as well as the bradycardic phase [C57: −2.9 ± 0.57 bpm/mmHg, SOD1: −4.3 ± 0.84 bpm/mmHg; ]. Even though there was a trend of increased BRS for SOD1 animals during the bradycardic phase, the slopes of the regression lines were not significantly different. Therefore, overexpression of hSOD1 did not significantly change baroreflex-mediated tachycardia and bradycardia.
3.3. Aortic Depressor Nerve Function
Aortic depressor nerve function was measured as the aortic depressor nerve activity (ADNA) decreases in response to SNP/PE-induced AP elevation. Figure 3 shows the original recordings of typical burst ADNA in synchrony with PAP. Figures 4(a) and 4(b) show the original recordings of ADNA in response to changes in blood pressure in representative C57 and SOD1 mice. SNP injection decreased and PE injection increased ADNA. Int. ADNA and MAP relationship curves were fitted using the logistic sigmodal function in these two mice as shown in Figures 4(a′) and 4(b′). The averaged parameters of the logistic function curves (Table 2) show that the SOD1 animals had a significantly larger maximal Int. ADNA response () compared to C57 (). The maximal gain of the ADNA response () was also significantly greater in SOD1 than C57 (), indicating that hSOD1 overexpression resulted in more sensitive responses than the control, thus increasing the aortic baroreceptor depressor nerve function. The plots of the sigmoid logistic function curves of the averaged Int. ADNA-MAP relationship for C57 and SOD1 mice were shown in Figure 5.
In this study, we demonstrated that the overexpression of human SOD1 in mice does not have significant effect on AP, HR, or SNP/PE-induced changes of MAP and BRS as compared to controls. However, SOD1 overexpression enhanced baroreceptor depressor nerve function in response to AP elevation. While we could not fully interpret the mechanism, Li et al.  measured a similar increase in baroreceptor sensitivity after application of SOD1 and catalase to the nodose ganglia of healthy rabbits, though the effect was mild and not reversed by washout of the SOD or catalase.
4.1. hSOD1 Overexpression Did Not Change Basal Blood Pressure and Heart Rate
Superoxide radicals have profound effects in the modulation of neural activity in the brain stem [24, 59], and it is known that increases in ROS alter autonomic regulation of blood pressure [24, 60, 61]. One of the concerns of using the SOD1 mouse line is that interference with superoxide-dependent signaling in the brainstem by hSOD1 overexpression would alter basal HR and MAP. It is fairly well established that treatments with antioxidants may lead to changes of autonomic regulation in normal and disease models. hSOD1 overexpression in the paraventricular nucleus was found to reduce sympathetic activity and attenuate hypertension in spontaneously hypertensive rats, although no effect was detectable in the Wistar controls . Another study found that endothelial-specific catalase overexpression caused a significant reduction in blood pressure in healthy mice . Systemic administration of tempol, a SOD mimic , has previously been found to reduce MAP, HR, and renal sympathetic nerve activity (RSNA) in both normal and baroreceptor denervated rats . The same study noted reduced spontaneous discharge rate of neurons in the paraventricular nucleus of the hypothalamus (PVN) and the rostral ventrolateral medulla (RVLM), two critical nuclei involved in sympathetic regulation of the cardiovascular system. A similar study performed on normotensive WKY and spontaneously hypertensive (SHR) rats also demonstrated reduced HR and MAP during systemic tempol administration in both groups of animals, as well as decreased splanchnic nerve activity . Kawada’s study determined that the reduction in blood pressure was not caused by changes in peripheral vascular tone in WKY animals, although AP reduction was associated with relaxation of vascular tone in the SHR rats. Taken together, these prior studies raise the possibility that superoxide radical scavenging may have effects on neural and vascular control of blood pressure in diseased and healthy animals.
In our study, hSOD1 overexpression had no significant effect on MAP, HR, and BRS in healthy mice. This is in agreement with a previously published report  showing blood pressure equivalence between C57bl/6J mice and 6-TgN(SOD1)3Cje mice with a 3-fold overexpression of hSOD1 (Jackson Catalog#: 002629). Therefore, hSOD1 overexpression in healthy animals does not seem to compromise basic hemodynamic stability as measured by HR and AP.
4.2. Baroreflex Control of Heart Rate Not Significantly Affected by hSOD1 Overexpression
Previous studies have shown that redox species modulate the activity of baroreceptor neurons [20–23], NTS [24–26], sympathetic brain stem nuclei such as the PVN  and RVLM [28–30], and intrinsic cardiac ganglia . Perturbations in the function of any of the components of the baroreflex loop can alter baroreflex sensitivity and function. Indeed, it is well established that increased ROS levels in these components can reduce baroreflex sensitivity and response [26, 31, 61]. However, the effect of long-term antioxidant supplementation, and in particular SOD1 overexpression, on baroreflex function in healthy animals was less well documented. Li et al.  found that exogenous SOD1 or catalase applied to the carotid sinus caused a small but significant increase in baroreceptor activity between the pressures of 60 and 80 mmHg but did not increase the maximal baroreceptor activation. However, this study did not measure HR response to blood pressure ramps (ΔHR/ΔMAP), so it is uncertain if local application of SOD or catalase to the carotid baroreceptors would have had an appreciable effect on the baroreflex control of heart rate. Guimarães et al.  investigated the effects of NADPH-derived superoxide anion reductions by IV Tiron (a superoxide anion scavenger, ) or apocynin (NADPH oxidase inhibitor, ) on BRS in WKY and SHR rats and found that the acute application of these agents had no significant effect on BRS in healthy animals, although they improved BRS in the hypertensive animals. Unfortunately, this still does not give any indication as to what effects long-term superoxide anion scavenging could have on BRS. The results of our investigation suggest for the first time that moderate (~3.5-fold, ) chronic systemic hSOD1 overexpression does not significantly impact baroreflex sensitivity in healthy animals.
4.3. Baroreceptor Afferent Function Enhanced by Overexpression of Human SOD1
As shown in Figure 5, we found that hSOD1 overexpressing mice showed significantly increased aortic baroreceptor activation slope and gain compared to C57 controls. This result is similar to the finding of Li et al. , who reported that carotid sinus nerve (CSN) activation in response to BP ramps was enhanced by application of SOD or catalase to the carotid sinus in rabbits.
Defining the mechanism the observed increase in baroreceptor activation is beyond the scope of this investigation, but there are certainly precedents in the literature. SOD1 is known to support nitrous oxide (NO) mediated vasorelaxation , which improves arterial compliance [71–73]. A high degree of vascular compliance is linked to robust baroreflex sensitivity [9, 74, 75], which decreases in step with vascular compliance. There is research that supports the hypothesis that antioxidant supplementation can improve large artery compliance [76, 77].
SOD1 may directly affect the mechanosensory properties of the aortic baroreceptor terminals by altering the expression or activity of critical ion channels in the baroreceptor terminals. There is evidence that ROS inhibit the expression of ASIC2 (Acid-Sensitive Ion Channel) which is critical to mechanotransduction of arterial pressure [78, 79]. ASIC2 expression is downregulated in SHR rats [80, 81], which show a similar diminution of baroreceptor activation to ASIC2 null mice . Application of the superoxide mimetic tempol to nodose ganglia cells in either the ASIC2 null mice or SHR rats has been shown to restore baroreflex activation of baroreceptor neurons to near normal levels . Hyperpolarization-activated cyclic nucleotide (HCN) channels, which are also strongly linked to mechanoreception in arterial baroreceptors, are shown to be upregulated in type 1 diabetes mellitus leading to a reduced baroreceptor function that can be rescued with tempol .
A growing body of evidence has shown that interventions based on antioxidants can be effective in reducing hypertension, increasing vascular compliance and function, and improving baroreflex-mediated control of heart rate [25, 27, 32, 33, 66, 76]. However, because ROS have a wide variety of necessary biological functions, it is important to evaluate the effect of systemic application of antioxidants on cardiac autonomic function in the absence of any other diseases. The current study uses a transgenic mouse model based on the C57bl/6j mouse line which has been engineered to express human Cu/ZnSOD (SOD1) at a level roughly 3.5-fold over normal murine SOD1 expression in cortical tissue . This transgenic mouse line was originally developed in 1994 as a gene-dosage control for a mouse model of amyotrophic lateral sclerosis (ALS) overexpressing a SOD1-G93A mutation. The SOD1 mouse line used in this study showed no signs of ALS-like symptoms. In addition, Dal Canto and Gurney  also performed anatomical assessment of neural tissue and found that the mice overexpressing hSOD1 showed very subtle changes in the anterior portion of the anterior horn (mild swelling of motor fibers and vacuolization of dendrites) but were free of any ALS-like symptoms . Functionally, there were no signs of impaired motor performance until 58 weeks of age. tgSOD1 mice in the current experiment were between 12 and 16 weeks of age, well before the window in which motor function changes are observed. In our study, we did not find any changes in AP, HR, vasoactive drugs-induced hypo- and hypertension, and BRS. Noticeably, the aortic depressor nerve function is increased in hSOD1 mice. Even though we could not interpret the mechanism for such an enhancement of aortic depressor nerve function, it appears that hSOD1 overexpression in this line of mouse did not impair but may have increased the function of baroreceptor afferent components in the baroreflex arc. Interestingly, Xu et al.  reported that mice overexpressing hSOD1, the same model as the one we used in present study, showed increased resistance to oxidative stress and apoptosis of cortical neurons after exposure to chronic intermittent hypoxia compared to wild-type control. hSOD1 overexpression has also been shown to protect against mitochondrial cytochrome C release and subsequent apoptosis in focal cerebral ischemia models of stroke . Since our data indicate that hSOD1 overexpression did not cause dysfunction of MAP, HR, and BRS but may increase aortic baroreceptor nerve function, we suggest that this model can be potentially used to study whether increased expression of hSOD1 protects against disease (such as chronic intermittent hypoxia and diabetes-) induced impairment of baroreflex sensitivity, vagal motor neuron death in the nucleus ambiguus, and degeneration of vagal afferent and efferent axons in the aortic arch and cardiac ganglion shown in the previous studies [51, 52, 55, 84–86]. Whether the increased baroreceptor sensitivity in healthy animals may prove advantageous in mitigating disease-induced impairment of autonomic control of the heart is a promising concept, and we are currently using our hSOD1 overexpressing mice to determine if hSOD1 overexpression can preserve normal afferent, efferent, and central components of the baroreflex arc in the CIH model of sleep apnea.
It should be pointed out that since baroreflex-mediated reduction of heart rate in response to increased arterial pressure had a trend of increase but not significantly, it appears that the increased signaling from the aortic depressor baroreceptor nerves to the brainstem is buffered by other neural components of the baroreflex loop, such as the NTS, NA, or cardiac ganglia within the heart. Whether such a buffering is a product of normal physiologic compensation or something of a more pathologic nature is undetermined. Thus, careful studies of other neural components in the baroreflex arc in addition to aortic depressor nerves are critically important to fully understand the effects of hSOD overexpression on the whole baroreflex circuitry.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
- A. R. Olshan, D. T. O'connor, I. M. Cohen, J. A. Mitas, and R. A. Stone, “Baroreflex dysfunction in patients with adult-onset diabetes and hypertension,” The American Journal of Medicine, vol. 74, no. 2, pp. 233–242, 1983.
- R. E. Maser and M. J. Lenhard, “Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 10, pp. 5896–5903, 2005.
- A. I. Vinik, R. E. Maser, B. D. Mitchell, and R. Freeman, “Diabetic autonomic neuropathy,” Diabetes Care, vol. 26, no. 5, pp. 1553–1579, 2003.
- E. D. Moreira, F. Ida, V. L. L. Oliveira, and E. M. Krieger, “Early depression of the baroreceptor sensitivity during onset of hypertension,” Hypertension, vol. 19, no. 2, supplement, pp. II198–II201, 1992.
- K. Narkiewicz and V. K. Somers, “Cardiovascular variability characteristics in obstructive sleep apnea,” Autonomic Neuroscience: Basic & Clinical, vol. 90, no. 1-2, pp. 89–94, 2001.
- T. B. J. Kuo, T. Lin, C. C. H. Yang, C.-L. Li, C.-F. Chen, and P. Chou, “Effect of aging on gender differences in neural control of heart rate,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 277, no. 6, part 2, pp. H2233–H2239, 1999.
- M. Saint Martin, F. Roche, C. Thomas-Anterion, J. C. Barthélémy, and E. Sforza, “Eight-year parallel change in baroreflex sensitivity and memory function in a sample of healthy older adults,” Journal of the American Geriatrics Society, vol. 63, no. 2, pp. 270–275, 2015.
- J.-P. Fauvel, C. Cerutti, I. Mpio, and M. Ducher, “Aging process on spectrally determined spontaneous baroreflex sensitivity: a 5-year prospective study,” Hypertension, vol. 50, no. 3, pp. 543–546, 2007.
- K. D. Monahan, “Effect of aging on baroreflex function in humans,” American Journal of Physiology: Regulatory Integrative and Comparative Physiology, vol. 293, no. 1, pp. R3–R12, 2007.
- C. J. Lai, C. C. H. Yang, Y. Y. Hsu, Y. N. Lin, and T. B. J. Kuo, “Enhanced sympathetic outflow and decreased baroreflex sensitivity are associated with intermittent hypoxia-induced systemic hypertension in conscious rats,” Journal of Applied Physiology, vol. 100, no. 6, pp. 1974–1982, 2006.
- G. A. Ford, “Ageing and the baroreflex,” Age and Ageing, vol. 28, no. 4, pp. 337–338, 1999.
- M. D. Thames, T. Kinugawa, M. L. Smith, and M. E. Dibner-Dunlap, “Abnormalities of baroreflex control in heart failure,” Journal of the American College of Cardiology, vol. 22, no. 4, supplement 1, pp. A56–A60, 1993.
- K. J. Osterziel, D. Hänlein, R. Willenbrock, C. Eichhorn, F. Luft, and R. Dietz, “Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure,” British Heart Journal, vol. 73, no. 6, pp. 517–522, 1995.
- A. Mortara, M. T. La Rovere, G. D. Pinna et al., “Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications,” Circulation, vol. 96, no. 10, pp. 3450–3458, 1997.
- N. Okada, N. Takahashi, K. Yufu et al., “Baroreflex sensitivity predicts cardiovascular events in patients with type 2 diabetes mellitus without structural heart disease,” Circulation Journal, vol. 74, no. 7, pp. 1379–1383, 2010.
- B. H. Machado, “Neurotransmission of the cardiovascular reflexes in the nucleus tractus solitarii of awake rats,” Annals of the New York Academy of Sciences, vol. 940, pp. 179–196, 2001.
- R. A. L. Dampney, “Functional organization of central pathways regulating the cardiovascular system,” Physiological Reviews, vol. 74, no. 2, pp. 323–364, 1994.
- R. A. L. Dampney, M. J. Coleman, M. A. P. Fontes et al., “Central mechanisms underlying short- and long-term regulation of the cardiovascular system,” Clinical and Experimental Pharmacology & Physiology, vol. 29, no. 4, pp. 261–268, 2002.
- R. A. L. Dampney, J. Horiuchi, S. Killinger, M. J. Sheriff, P. S. P. Tan, and L. M. McDowall, “Long-term regulation of arterial blood pressure by hypothalamic nuclei: some critical questions,” Clinical and Experimental Pharmacology & Physiology, vol. 32, no. 5-6, pp. 419–425, 2005.
- L. Zhang, H. Tu, and Y.-L. Li, “Angiotensin II enhances hyperpolarization-activated currents in rat aortic baroreceptor neurons: Involvement of superoxide,” American Journal of Physiology: Cell Physiology, vol. 298, no. 1, pp. C98–C106, 2009.
- Y.-J. Peng, J. Nanduri, X. Zhang et al., “Endothelin-1 mediates attenuated carotid baroreceptor activity by intermittent hypoxia,” Journal of Applied Physiology, vol. 112, no. 1, pp. 187–196, 2012.
- Y. L. Li, “Angiotensin II-superoxide signaling and arterial baroreceptor function in type-1 diabetes mellitus,” Journal of Diabetes & Metabolism, vol. supplement 12, pp. 1–6, 2013.
- Y. Ding, Y.-L. Li, M. C. Zimmerman, R. L. Davisson, and H. D. Schultz, “Role of CuZn superoxide dismutase on carotid body function in heart failure rabbits,” Cardiovascular Research, vol. 81, no. 4, pp. 678–685, 2009.
- Y. Hirooka, “Role of reactive oxygen species in brainstem in neural mechanisms of hypertension,” Autonomic Neuroscience: Basic & Clinical, vol. 142, no. 1-2, pp. 20–24, 2008.
- M. Nozoe, Y. Hirooka, Y. Koga et al., “Inhibition of Rac1-derived reactive oxygen species in nucleus tractus solitarius decreases blood pressure and heart rate in stroke-prone spontaneously hypertensive rats,” Hypertension, vol. 50, no. 1, pp. 62–68, 2007.
- C.-Y. Tsai, C.-H. Su, V. Baudrie et al., “Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model,” NeuroImage, vol. 82, pp. 190–199, 2013.
- N. Yuan, F. Zhang, L.-L. Zhang et al., “SOD1 gene transfer into paraventricular nucleus attenuates hypertension and sympathetic activity in spontaneously hypertensive rats,” Pflugers Archiv, vol. 465, no. 2, pp. 261–270, 2012.
- T. Kishi, Y. Hirooka, Y. Kimura, K. Ito, H. Shimokawa, and A. Takeshita, “Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats,” Circulation, vol. 109, no. 19, pp. 2357–2362, 2004.
- L. Gao, W. Wang, Y.-L. Li et al., “Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase,” Circulation Research, vol. 95, no. 9, pp. 937–944, 2004.
- L. Gao, W. Wang, D. Liu, and I. H. Zucker, “Exercise training normalizes sympathetic outflow by central antioxidant mechanisms in rabbits with pacing-induced chronic heart failure,” Circulation, vol. 115, no. 24, pp. 3095–3102, 2007.
- Z. Li, H. Z. Mao, F. M. Abboud, and M. W. Chapleau, “Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits,” Circulation Research, vol. 79, no. 4, article 802, 1996.
- T. Kawada, Y. Sata, S. Shimizu, M. J. Turner, M. Fukumitsu, and M. Sugimachi, “Effects of tempol on baroreflex neural arc versus peripheral arc in normotensive and spontaneously hypertensive rats,” American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, vol. 308, no. 11, pp. R957–R964, 2015.
- S. Gouty, J. Regalia, F. Cai, and C. J. Helke, “α-Lipoic acid treatment prevents the diabetes-induced attenuation of the afferent limb of the baroreceptor reflex in rats,” Autonomic Neuroscience, vol. 108, no. 1-2, pp. 32–44, 2003.
- S.-G. Wei, Z.-H. Zhang, Y. Yu, and R. B. Felder, “Systemically administered tempol reduces neuronal activity in paraventricular nucleus of hypothalamus and rostral ventrolateral medulla in rats,” Journal of Hypertension, vol. 27, no. 3, pp. 543–550, 2009.
- H. J. Forman, M. Maiorino, and F. Ursini, “Signaling functions of reactive oxygen species,” Biochemistry, vol. 49, no. 5, pp. 835–842, 2010.
- V. A. Braga, I. A. Medeiros, T. P. Ribeiro, M. S. França-Silva, M. S. Botelho-Ono, and D. D. Guimarães, “Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension,” Brazilian Journal of Medical and Biological Research, vol. 44, no. 9, pp. 871–876, 2011.
- V. M. Campese, S. Ye, H. Zhong, V. Yanamadala, Z. Ye, and J. Chiu, “Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 287, no. 2, pp. H695–H703, 2004.
- D. Jaarsma, E. D. Haasdijk, J. A. C. Grashorn et al., “Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1,” Neurobiology of Disease B, vol. 7, no. 6, pp. 623–643, 2000.
- M. C. Dal Canto and M. E. Gurney, “Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS),” Brain Research, vol. 676, no. 1, pp. 25–40, 1995.
- H. J. Fullerton, J. S. Ditelberg, S. F. Chen et al., “Copper/zinc superoxide dismutase transgenic brain accumulates hydrogen peroxide after perinatal hypoxia ischemia,” Annals of Neurology, vol. 44, no. 3, pp. 357–364, 1998.
- P. Amstad, A. Peskin, G. Shah et al., “The balance between Cu,Zn-superoxide dismutase and catalase affects the sensitivity of mouse epidermal cells to oxidative stress,” Biochemistry, vol. 30, no. 38, pp. 9305–9313, 1991.
- O. Bar-Peled, E. Korkotian, M. Segal, and Y. Groner, “Constitutive overexpression of Cu/Zn superoxide dismutase exacerbates kainic acid-induced apoptosis of transgenic-Cu/Zn superoxide dismutase neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8530–8535, 1996.
- K. Kotulska, M. LePecheur, W. Marcol et al., “Overexpression of copper/zinc-superoxide dismutase in transgenic mice markedly impairs regeneration and increases development of neuropathic pain after sciatic nerve injury,” Journal of Neuroscience Research, vol. 84, no. 5, pp. 1091–1097, 2006.
- J. M. McCord and M. A. Edeas, “SOD, oxidative stress and human pathologies: a brief history and a future vision,” Biomedicine & Pharmacotherapy, vol. 59, no. 4, pp. 139–142, 2005.
- J. M. McCord, “Superoxide dismutase, lipid peroxidation, and bell-shaped dose response curves,” Dose Response, vol. 6, no. 3, article 223, 2008.
- B. W. Brooksbank and R. Balazs, “Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain,” Brain Research, vol. 318, no. 1, pp. 37–44, 1984.
- G. T. Capone, “Down syndrome: advances in molecular biology and the neurosciences,” Journal of Developmental & Behavioral Pediatrics, vol. 22, no. 1, pp. 40–59, 2001.
- C. J. Epstein, K. B. Avraham, M. Lovett et al., “Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 22, pp. 8044–8048, 1987.
- J. Ai, D. Gozal, L. Li et al., “Degeneration of vagal efferent axons and terminals in cardiac ganglia of aged rats,” Journal of Comparative Neurology, vol. 504, no. 1, pp. 74–88, 2007.
- J. Ai, R. D. Wurster, S. W. Harden, and Z. J. Cheng, “Vagal afferent innervation and remodeling in the aortic arch of young-adult fischer 344 rats following chronic intermittent hypoxia,” Neuroscience, vol. 164, no. 2, pp. 658–666, 2009.
- H. Gu, M. Lin, J. Liu et al., “Selective impairment of central mediation of baroreflex in anesthetized young adult Fischer 344 rats after chronic intermittent hypoxia,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 5, pp. H2809–H2818, 2007.
- H. Gu, P. N. Epstein, L. Li, R. D. Wurster, and Z. J. Cheng, “Functional changes in baroreceptor afferent, central and efferent components of the baroreflex circuitry in type 1 diabetic mice (OVE26),” Neuroscience, vol. 152, no. 3, pp. 741–752, 2008.
- H. Gu, Z.-H. Zhang, P. N. Epstein et al., “Impaired baroreflex control of renal sympathetic nerve activity in type 1 diabetic mice (OVE26),” Neuroscience, vol. 161, no. 1, pp. 78–85, 2009.
- L. Li, C. Huang, J. Ai et al., “Structural remodeling of vagal afferent innervation of aortic arch and nucleus ambiguus (NA) projections to cardiac ganglia in a transgenic mouse model of type 1 diabetes (OVE26),” The Journal of Comparative Neurology, vol. 518, no. 14, pp. 2771–2793, 2010.
- M. Lin, R. Liu, D. Gozal et al., “Chronic intermittent hypoxia impairs baroreflex control of heart rate but enhances heart rate responses to vagal efferent stimulation in anesthetized mice,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 293, no. 2, pp. H997–H1006, 2007.
- M. Lin, J. Ai, L. Li et al., “Structural remodeling of nucleus ambiguus projections to cardiac ganglia following chronic intermittent hypoxia in C57BL/6J mice,” Journal of Comparative Neurology, vol. 509, no. 1, pp. 103–117, 2008.
- M. Lin, J. Ai, S. W. Harden et al., “Impairment of baroreflex control of heart rate and structural changes of cardiac ganglia in conscious streptozotocin (STZ)-induced diabetic mice,” Autonomic Neuroscience: Basic & Clinical, vol. 155, no. 1-2, pp. 39–48, 2010.
- B. B. Kent, J. W. Drane, B. Blumenstein, and J. W. Manning, “A mathematical model to assess changes in the baroreceptor reflex,” Cardiology, vol. 57, no. 5, pp. 295–310, 1972.
- M. C. Zimmerman and R. L. Davisson, “Redox signaling in central neural regulation of cardiovascular function,” Progress in Biophysics and Molecular Biology, vol. 84, no. 2-3, pp. 125–149, 2004.
- S. R. Datla and K. K. Griendling, “Reactive oxygen species, NADPH oxidases, and hypertension,” Hypertension, vol. 56, no. 3, pp. 325–330, 2010.
- S. H. H. Chan and J. Y. H. Chan, “Brain stem NOS and ROS in neural mechanisms of hypertension,” Antioxidants & Redox Signaling, vol. 20, no. 1, pp. 146–163, 2014.
- T. Suvorava and G. Kojda, “Reactive oxygen species as cardiovascular mediators: lessons from endothelial-specific protein overexpression mouse models,” Biochimica et Biophysica Acta, vol. 1787, no. 7, pp. 802–810, 2009.
- C. Muscoli, S. Cuzzocrea, D. P. Riley et al., “On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies,” British Journal of Pharmacology, vol. 140, no. 3, pp. 445–460, 2003.
- H. D. Wang, D. G. Johns, S. Xu, and R. A. Cohen, “Role of superoxide anion in regulating pressor and vascular hypertrophic response to angiotensin II,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 282, no. 5, pp. H1697–H1702, 2002.
- K. A. Whyte, R. C. Hogg, J. Dyavanapalli, A. A. Harper, and D. J. Adams, “Reactive oxygen species modulate neuronal excitability in rat intrinsic cardiac ganglia,” Autonomic Neuroscience: Basic & Clinical, vol. 150, no. 1-2, pp. 45–52, 2009.
- D. D. Guimarães, C. C. Carvalho, and V. A. Braga, “Scavenging of NADPH oxidase-derived superoxide anions improves depressed baroreflex sensitivity in spontaneously hypertensive rats,” Clinical and Experimental Pharmacology and Physiology, vol. 39, no. 4, pp. 373–378, 2012.
- A. N. Ledenev, A. A. Konstantinov, E. Popova, and E. K. Ruuge, “A simple assay of the superoxide generation rate with Tiron as an EPR-visible radical scavenger,” Biochemistry international, vol. 13, no. 2, pp. 391–396, 1986.
- M. S. Petrônio, M. L. Zeraik, L. M. Da Fonseca, and V. F. Ximenes, “Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor,” Molecules, vol. 18, no. 3, pp. 2821–2839, 2013.
- M. E. Gurney, H. Pu, A. Y. Chiu et al., “Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation,” Science, vol. 264, no. 5166, pp. 1772–1775, 1994.
- T. Fukai and M. Ushio-Fukai, “Superoxide dismutases: role in redox signaling, vascular function, and diseases,” Antioxidants and Redox Signaling, vol. 15, no. 6, pp. 1583–1606, 2011.
- S. P. Didion, M. J. Ryan, L. A. Didion, P. E. Fegan, C. D. Sigmund, and F. M. Faraci, “Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice,” Circulation Research, vol. 91, no. 10, pp. 938–944, 2002.
- S. P. Didion, M. J. Ryan, G. L. Baumbach, C. D. Sigmund, and F. M. Faraci, “Superoxide contributes to vascular dysfunction in mice that express human renin and angiotensinogen,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 283, no. 4, pp. H1569–H1576, 2002.
- S. M. Lynch, B. Frei, J. D. Morrow et al., “Vascular superoxide dismutase deficiency impairs endothelial vasodilator function through direct inactivation of nitric oxide and increased lipid peroxidation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2975–2981, 1997.
- K. D. Monahan, H. Tanaka, F. A. Dinenno, and D. R. Seals, “Central arterial compliance is associated with age- and habitual exercise-related differences in cardiovagal baroreflex sensitivity,” Circulation, vol. 104, no. 14, pp. 1627–1632, 2001.
- F. Michas, E. Manios, K. Stamatelopoulos et al., “Baroreceptor reflex sensitivity is associated with arterial stiffness in a population of normotensive and hypertensive patients,” Blood Pressure Monitoring, vol. 17, no. 4, pp. 155–159, 2012.
- M. Shargorodsky, O. Debby, Z. Matas, and R. Zimlichman, “Effect of long-term treatment with antioxidants (vitamin C, vitamin E, coenzyme Q10 and selenium) on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors,” Nutrition & Metabolism, vol. 7, article 55, 2010.
- S. Ülker, P. P. McKeown, and U. Bayraktutan, “Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities,” Hypertension, vol. 41, no. 3, pp. 534–539, 2003.
- F. M. Abboud, “The Walter B. Cannon memorial award lecture, 2009. Physiology in perspective: the wisdom of the body. In search of autonomic balance: the good, the bad, and the ugly,” American Journal of Physiology—Regulatory, Integrative and Comparative Physiology, vol. 298, no. 6, pp. R1449–R1467, 2010.
- Y. Lu, X. Ma, R. Sabharwal et al., “The ion channel ASIC2 is required for baroreceptor and autonomic control of the circulation,” Neuron, vol. 64, no. 6, pp. 885–897, 2009.
- Y. Lu, C. A. Whiteis, M. W. Chapleau, and F. M. Abboud, “Decreased mRNA expression of ASIC2a in nodose sensory ganglia is associated with development of hypertension in SHR (abstract),” The FASEB Journal, vol. 21, p. A1405, 2007.
- V. Snitsarev, K. Iyer, C. A. Whiteis, M. W. Chapleau, and F. M. Abboud, “Novel molecular defects in mechanosensitivity of aortic baroreceptor neurons from spontaneously hypertensive rats (Abstract),” The FASEB Journal, vol. 19, p. A607, 2005.
- W. Xu, L. Chi, B. W. Row et al., “Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea,” Neuroscience, vol. 126, no. 2, pp. 313–323, 2004.
- M. Fujimura, Y. Morita-Fujimura, N. Noshita, T. Sugawara, M. Kawase, and P. H. Chan, “The cytosolic antioxidant copper/zinc-superoxide dismutase prevents the early release of mitochondrial cytochrome c in ischemic brain after transient focal cerebral ischemia in mice,” Journal of Neuroscience, vol. 20, no. 8, pp. 2817–2824, 2000.
- B. Yan, G. K. Soukhova-O'Hare, L. Li et al., “Attenuation of heart rate control and neural degeneration in nucleus ambiguus following chronic intermittent hypoxia in young adult Fischer 344 rats,” Neuroscience, vol. 153, no. 3, pp. 709–720, 2008.
- B. Yan, H. Li, S. W. Harden et al., “Chronic intermittent hypoxia impairs heart rate responses to AMPA and NMDA and induces loss of glutamate receptor neurons in nucleus ambiguus of F344 rats,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 296, no. 2, pp. R299–R308, 2009.
- B. Yan, L. Li, S. W. Harden, P. N. Epstein, R. D. Wurster, and Z. J. Cheng, “Diabetes induces neural degeneration in nucleus ambiguus (NA) and attenuates heart rate control in OVE26 mice,” Experimental Neurology, vol. 220, no. 1, pp. 34–43, 2009.
Copyright © 2016 Jeffrey Hatcher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.